# Beam Therapeutics
 (stock symbol: BEAM) Logo in transparent PNG format

## Beam Therapeutics
 Logo large

### Beam Therapeutics
 Logo large Download PNG (70.19 KB)

![Beam Therapeutics
 Logo large Download PNG (70.19 KB)](/img/orig/BEAM_BIG-44130aa2.png)

## Beam Therapeutics
 Logo icon format

### Beam Therapeutics
 Logo icon format Download PNG (78.72 KB)

![Beam Therapeutics
 Logo icon format Download PNG (78.72 KB)](/img/orig/BEAM-7bc6b983.png)

## About Beam Therapeutics


Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

1. Website domain: beamtx.com
2. Employees: 476
3. Marketcap: $2.29 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ CRISPR
- [x] ðŸ§¬ Biotech
- [x] ðŸ§¬ Genomics
- [x] ðŸ§¬ Gene therapy
